AltruBio

AltruBio is a biotechnology company focused on developing novel antibody therapies for the treatment of immune-mediated diseases with unmet medical needs. Based on unique insights into immune tolerance and epitope dominance science, AltruBio's pipeline includes two clinical-stage product candidates: (i) Neihulizumab (AbGn-168H), an immune checkpoint agonist antibody targeting PSGL-1/CD162 that depletes unwanted activated T cells and has demonstrated mechanisms in four autoimmune and inflammatory diseases, and (ii) AbGn-107, an antibody-drug conjugate (ADC) utilizing a unique enzymatically-cleavable self-immolative linker, targeting gastrointestinal tumor antigens. AbGn-107 has shown encouraging results in chemotherapy-refractory gastric cancer, pancreatic cancer, colorectal cancer, and biliary tract cancer.